SCHEMBL13745451

SCHEMBL13745451

C=C(O)c1ccccc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 1/20 0.38
PTPN2 P17706 2/20 0.36
PTPN1 P18031 2/20 0.36
PTPRF P10586 1/20 0.36
ABL1 P00519 1/20 0.34
SRC P12931 1/20 0.34
KDM4E B2RXH2 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
HMGB1 P09429 1/20 0.32
HPGD P15428 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA7 P43166 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21969580 0.80 ALDH1A1 (0.47) TDP1ALDH1A1ALOX15SRCKDM4E
SCHEMBL22624389 0.79 MEN1 (0.42) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL16994141 0.78 MEN1 (0.42) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL7765253 0.77 MEN1 (0.41) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL22991616 0.77 MEN1 (0.41) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL29712372 0.77 MEN1 (0.41) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL6472175 0.77 MEN1 (0.50) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL4088432 0.75 MEN1 (0.46) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL30516691 0.74 ALDH1A1 (0.65) MEN1KMT2ATDP1ALDH1A1ALOX15
SCHEMBL40612 0.74 ALDH1A1 (0.65) MEN1KMT2ATDP1ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572829-B2 Pharmaceutical compositions useful in prevention and treatment of Beta-amyloid protein-induced disease KIM DARRICK S H L 2009-08-11 US disclosed
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease KIM DARRICK S 2008-04-10 US disclosed
US-7282523-B2 Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H L 2007-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease APP, BACE1, PSEN1 MEN1 882/4885KMT2A 4502/4885TDP1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.